Fragment-Based Drug Discovery 2013

Using fragment-based technologies for drug design has an established place in the toolkit of drug discovery. However, as the field is maturing, a new set of questions is emerging, such as how to select the most suitable projects, are there new screening developments, how about weak binding compounds – how does one screen for those? What are the best technologies to combine – and are there new applications one needs to know about? What are the pro's and con's of using FBDD?